Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research

Lisa Ellen Flaum*, William J Gradishar

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Endocrine therapies have played an important role in the management of breast cancer for many years. Tamoxifen had been the unchallenged standard in the adjuvant setting until recently. Data from recent clinical trials have emphasized the emerging roles of aromatase inhibitors and ovarian ablation in patients with early breast cancer. This review highlights previous data that led to the recognition of tamoxifen as the gold standard hormonal therapy in the adjuvant treatment of early breast cancer. We then discuss clinical trials demonstrating the impact of aromatase inhibitors as an alternative to tamoxifen or as a component of sequential treatment with tamoxifen in postmenopausal women with early breast cancer. Finally, we review data related to the incorporation of ovarian ablation into the treatment of early breast cancer in premenopausal women.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalCurrent Oncology Reports
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research'. Together they form a unique fingerprint.

  • Cite this